Core Insights - Crescent Biopharma has announced a strategic partnership with Kelun-Biotech to enhance its oncology pipeline, focusing on CR-001, a PD-1 x VEGF bispecific antibody, and several antibody-drug conjugates (ADCs) [1][3][4] - The company plans to initiate clinical trials for CR-001, CR-002, and CR-003 (SKB105) in 2026, with significant data readouts expected by the end of 2027 [1][2][10] - A private placement of $185 million is set to support clinical developments and provide a cash runway into 2028 [1][16][19] Partnership Details - The partnership grants Kelun-Biotech exclusive rights to develop and commercialize CR-001 in Greater China, while Crescent retains rights for SKB105 in the U.S., Europe, and other markets [4] - Both companies can independently develop CR-001 in additional combinations, including with proprietary ADC assets [4] Pipeline Updates - CR-001 is designed to target solid tumors by blocking PD-1 and VEGF, with a Phase 1/2 trial expected to start in Q1 2026 [11][12] - CR-002 targets PD-L1 and is on track for an IND submission in mid-2026, with proof-of-concept data anticipated in late 2027 [11][19] - CR-003 (SKB105) targets integrin beta-6 and is expected to enter clinical trials in Greater China in Q1 2026, with initial data expected in Q1 2027 [11][19] Financial Overview - The private placement involves the sale of approximately 13.8 million ordinary shares at $13.41 per share, expected to close around December 8, 2025 [17][19] - The net proceeds will be used for advancing clinical development and general corporate purposes, ensuring operations are funded into 2028 [19][20] Anticipated Milestones - Key milestones include the initiation of Phase 1/2 trials for CR-001 and CR-003 in 2026, with initial combination data from CR-001 and CR-003 expected by the end of 2027 [10][14][15]

Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the development of synergistic combinations with CR-001 and ADCs, including SKB105 CR-001 and SKB105 on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026 with combination studies to follow CHENGDU, China and WALTHAM, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sichuan Kelun-Biotech Biophar ...

Core Insights - Nuvation Bio Inc. (NYSE:NUVB) is recognized as one of the best American penny stocks to buy currently, with an increased price target from $6 to $8 by Citizens, maintaining a Market Outperform rating [1][2] Group 1: Company Performance - Nuvation Bio Inc. successfully initiated treatment for 204 patients with IBTROZI (taletrectinib) in Q3 2025, exceeding expectations and outperforming other recent ROS1 inhibitor launches [2][3] - The updated data for IBTROZI (taletrectinib) indicates unprecedented durability, leading Citizens to raise its short-term forecasts for Nuvation Bio Inc. [3] Group 2: Market Position - Nuvation Bio Inc. is a biopharmaceutical company focused on developing oncology therapeutics, particularly for ROS1-positive non-small cell lung cancer [3][4]

Core Viewpoint - Merus N.V. is participating in the 2025 Wells Fargo Healthcare Conference, highlighting its focus on innovative oncology therapies [1]. Company Overview - Merus N.V. specializes in developing full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics® [3]. - The company’s products, including Biclonics®, Triclonics®, and ADClonics®, are designed to have characteristics similar to conventional human monoclonal antibodies, such as long half-life and low immunogenicity [3]. Event Details - Bill Lundberg, M.D., President and CEO of Merus, will engage in a fireside chat at the conference on September 4, 2025, at 3:45 p.m. ET [1]. - The presentation will be available via webcast on the company's Investors page, with an archived version accessible for a limited time post-event [2].